RegulatoryCompany release
AEON Biopharma gets FDA Type 2b feedback on ABP-450 biosimilar route to BOTOX
🇺🇸 AEON Biopharma, Inc. (AEON) · Mon 16 Nov 2026
The US regulator has agreed in principle to a two-stage pharmacodynamic study and signalled that earlier Daewoong clinical data could be supportive, subject to bridging.
AEON Biopharma said on 16 November 2026, alongside its third-quarter results, that it has received minutes from a Type 2b meeting with the US Food and Drug Administration on developing ABP-450 as a biosimilar to BOTOX.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): AEON Biopharma, Inc. ↗
Article written by VigiEye from the official source (AEON Biopharma, Inc.). Claims are the company's own. AI-assisted; check the source before acting.
More Regulatory
All →
FDA approves Roche's Wilserdly with everolimus for ESR1-mutated advanced breast cancer
Roche · Mon 16 Nov 2026
FDA approves Roche's oral SERD Wilserdly with everolimus for ESR1-mutated breast cancer
F. Hoffmann-La Roche Ltd · Mon 16 Nov 2026
iMDx Pauses FDA De Novo Review of GraftAssureDx Kidney Rejection Test, Plans January Response
🇺🇸 Insight Molecular Diagnostics Inc. (IMDX) · Mon 16 Nov 2026
Cumberland to file ifetroban NDA for Duchenne cardiomyopathy under FDA rolling submission
🇺🇸 Cumberland Pharmaceuticals Inc (CPIX) · Mon 16 Nov 2026
Galectin files belapectin Phase 3 protocol with FDA as chairman converts $105.8M debt
🇺🇸 Galectin Therapeutics Inc (GALT) · Mon 16 Nov 2026
Apnimed's sleep apnoea drug AD109 awaits FDA decision with 28 February 2027 goal date
🇺🇸 Apnimed, Inc. (APMD) · Mon 16 Nov 2026